GRCE
Grace Therapeutics, Inc.·Healthcare
3.59
0.829%(−0.03)
Market ClosedLast Updated: — ET
52W L: $1.9852W H: $5.18
GRCE NEWS
defenseworld.net
Mar 27
Short Interest in Grace Therapeutics, Inc. (NASDAQ:GRCE) Expands By 300.8%
Grace Therapeutics, Inc. (NASDAQ: GRCE - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 13th, there was short interest totaling 1,565,407 shares, an increase of 300.8% from the February 26th total of 390,568 shares. Approximately 11.4% of the company's stock are sold short. Based on an
globenewswire.com
Mar 19
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
PRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that abstracts discussing the unmet medical needs and the potential benefits of GTx-104 have been accepted for presentation at two major medical conferences taking place in March 2026.
globenewswire.com
Feb 25
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
PRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in TD Cowen's 46th Annual Health Care Conference, to be held March 2-4, 2026 in Boston, MA.
globenewswire.com
Feb 12
Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON Safety Trial Data Presented at 2025 Society of Vascular and Interventional Neurology Annual Meeting Company Continues Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA Submission for GTx-104 for the Treatment of Patients with aSAH PRINCETON, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the quarter ended December 31, 2025.
defenseworld.net
Feb 5
Grace Therapeutics (GRCE) Expected to Announce Quarterly Earnings on Thursday
Grace Therapeutics (NASDAQ: GRCE - Get Free Report) is projected to release its Q3 2026 results before the market opens on Thursday, February 12th. Analysts expect Grace Therapeutics to post earnings of ($0.09) per share for the quarter. Parties can check the company's upcoming Q3 2026 earning summary page for the latest details on the call
